Can we spot late side effects in neuroblastoma survivors? new study aims to find out
NCT ID NCT06480526
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether it's possible to screen for long-term health problems in people who survived high-risk neuroblastoma. Researchers will evaluate survivors who finished treatment at least 2 years ago, using tests for heart, nerve, and other health issues. The goal is to see if enough survivors will take part in these comprehensive check-ups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
34 people
The number who actually took part.
- Started
-
Oct 2024
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All participants who meet eligibility criteria and consent to enrollment on the study.
- Ages
-
5 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participants were diagnosed with neuroblastoma at \< 18 years of age and categorized as high-risk at that time, according to INSS26 or INRGSS27 criteria. * Participants were treated for HR-NBL at SJCRH on NB2012 or as per NB2012. * Participants are ≥ 2 years from completion of therapy. Participants are 5 years of age or older. * Participant or legal guardian is able and willing to give informed consent. * Participants may choose to participate in all or a fraction of the proposed assessments; refusal to participate in some aspects of the study will not preclude their inclusion. * Participants must also complete enrollment on SJLIFE. Exclusion Criteria: * Inability or unwillingness of research participant or legal guardian/representative to give written informed consent. * Participants who had relapsed or refractory disease during or following completion of modern era treatment for HR-NBL. * Participants who are pregnant or breastfeeding. * Participants who are unable to read and understand English
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for High-risk neuroblastoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy boosts chemo against tough childhood cancer
- New antibody combo shows promise in tough childhood cancer
- Experimental cancer therapy targets tough tumors with radioactive precision
- New vaccine aims to train immune system to attack childhood cancer
- New drug combo shows promise against childhood cancer
- New hope for kids with tough cancer: drug combo trial launches